Indoco Remedies Limited — Investor Meet, 09-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Indoco Remedies delivered improved Q3 FY26 performance. Consolidated revenues reached 434.3 Cr, up 7.9% YoY, with EBITDA at 31.5 Cr (7.3% margin). International Formulations surged 26.2% to 135.6 Cr, driven by strong growth in US (+21.6%) and Europe (+36.9%). API business grew 24% to 34.4 Cr. Domestic formulations were flat, impacted by acute therapies, but prescriptions remain strong. Management anticipates 20%+ revenue growth for Europe and 30%+ for OTC next year, alongside improving margins from new product launches and operational efficiencies. Debt stands at 900 Cr, expected to reduce to 775-800 Cr by March 2027 with controlled capex. A confident outlook on future growth.